MX2023003431A - Formulacion farmaceutica. - Google Patents
Formulacion farmaceutica.Info
- Publication number
- MX2023003431A MX2023003431A MX2023003431A MX2023003431A MX2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulation
- mitapivat
- disintegrant
- diluent
- lubricant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083834P | 2020-09-25 | 2020-09-25 | |
| US202063107196P | 2020-10-29 | 2020-10-29 | |
| US202163238483P | 2021-08-30 | 2021-08-30 | |
| PCT/US2021/051957 WO2022067039A1 (en) | 2020-09-25 | 2021-09-24 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003431A true MX2023003431A (es) | 2023-05-12 |
Family
ID=78179552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003431A MX2023003431A (es) | 2020-09-25 | 2021-09-24 | Formulacion farmaceutica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230338283A1 (https=) |
| EP (1) | EP4216956A1 (https=) |
| JP (1) | JP2023542701A (https=) |
| KR (1) | KR20230074536A (https=) |
| AU (1) | AU2021347349A1 (https=) |
| CA (1) | CA3196829A1 (https=) |
| IL (1) | IL301596A (https=) |
| MX (1) | MX2023003431A (https=) |
| TW (1) | TW202228691A (https=) |
| WO (1) | WO2022067039A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2561132C2 (ru) | 2009-06-29 | 2015-08-20 | Аджиос Фармасьютикалз, Инк. | Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности |
| FI3307271T3 (fi) | 2015-06-11 | 2023-10-17 | Agios Pharmaceuticals Inc | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä |
| JP7275130B2 (ja) * | 2017-11-22 | 2023-05-17 | アジオス ファーマシューティカルズ, インコーポレイテッド | N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性形態 |
-
2021
- 2021-09-24 EP EP21791565.1A patent/EP4216956A1/en active Pending
- 2021-09-24 KR KR1020237013787A patent/KR20230074536A/ko active Pending
- 2021-09-24 TW TW110135559A patent/TW202228691A/zh unknown
- 2021-09-24 US US18/028,058 patent/US20230338283A1/en active Pending
- 2021-09-24 MX MX2023003431A patent/MX2023003431A/es unknown
- 2021-09-24 JP JP2023519000A patent/JP2023542701A/ja active Pending
- 2021-09-24 AU AU2021347349A patent/AU2021347349A1/en active Pending
- 2021-09-24 CA CA3196829A patent/CA3196829A1/en active Pending
- 2021-09-24 WO PCT/US2021/051957 patent/WO2022067039A1/en not_active Ceased
- 2021-09-24 IL IL301596A patent/IL301596A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230338283A1 (en) | 2023-10-26 |
| WO2022067039A1 (en) | 2022-03-31 |
| CA3196829A1 (en) | 2022-03-31 |
| KR20230074536A (ko) | 2023-05-30 |
| JP2023542701A (ja) | 2023-10-11 |
| IL301596A (en) | 2023-05-01 |
| TW202228691A (zh) | 2022-08-01 |
| AU2021347349A1 (en) | 2023-06-08 |
| EP4216956A1 (en) | 2023-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4706671A3 (en) | Conjugated hepcidin mimetics | |
| EP4685160A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| EP4410291A3 (en) | Erbb receptor inhibitors | |
| ZA201803678B (en) | Pharmaceutical composition | |
| WO2020086747A3 (en) | Ssao inhibitors and uses thereof | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| SG11201808607SA (en) | Medicine obtained by combining fxr agonist and arb | |
| WO2018183089A8 (en) | Compositions for treating and/or preventing cancer | |
| MY209101A (en) | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof | |
| WO2019178191A8 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| MY208983A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| PH12017502322A1 (en) | Therapeutic agent for fibrosis | |
| JOP20210061A1 (ar) | توصيل مستمر لبولي ببتيدات 3 تشبه أنجيوبويتين | |
| MX2022007707A (es) | Comprimidos de edoxaban. | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| PH12021551985A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| MX2020008761A (es) | Productos alimenticios prebióticos en gomita. | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| MY207759A (en) | Pharmaceutical drug containing heterocyclidene acetamide derivative | |
| MX2021013488A (es) | Formulaciones liquidas de dosis oral de metilnaltrexona. | |
| MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
| MX2023003431A (es) | Formulacion farmaceutica. | |
| MX2021005681A (es) | Combinacion de un inhibidor de mcl-1 y midostaurina, usos y composiciones farmaceuticas de la misma. | |
| MX2023012930A (es) | Formulacion de sotorasib. | |
| WO2020247565A8 (en) | Oral care composition |